Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
Schiller
Advantech Europe

Zoll Acquires Intellectual Assets of Coaxia

By HospiMedica International staff writers
Posted on 15 Jul 2013
ZOLL (Chelmsford, MA, USA) has purchased the assets of CoAxia (Maple Grove, MN, USA), an early revenue stage medical device company that provides catheter-based perfusion augmentation therapies.

The core application ofCoAxia’s catheter technology, distributed under the trade names NeuroFlo and FloControl, involves the redistribution of blood flow from the lower extremities to support brain function during cerebral ischemia resulting from vasospasm, following subarachnoid hemorrhage. CoAxia did not have the funds to continue development after its de novo petition for the NeuroFlo catheter was rejected by the US Food and Drug Administration (FDA) for acute ischemic stroke. Zoll, however, still sees opportunity for the device and plans to design a new pivotal trial to take before the FDA.

Both NeuroFlo and FloControl blood flow redistribution technology use dual balloons to create temporary partial obstruction in the descending aorta. This technique causes a redistribution of cardiac output from the lower extremities to the cerebral vasculature without significantly increasing arterial blood pressure. The acquisition of the intellectual property also includes several key patents on cerebral perfusion augmentation as well as numerous other patents relevant to other various vascular procedures. Financial terms of the purchase were not disclosed.

“NeuroFlo technology has the potential to address a large portion of the population who suffer cerebral ischemia, offering a significant benefit to patients and the healthcare system,” said James Palazzolo, president of Zoll. “Our task is to continue to develop the significant body of clinical evidence started by CoAxia demonstrating the safety and efficacy of the NeuroFlo catheter and, in the end, do what is necessary for it to be a standard treatment option for hundreds of thousands of stroke patients worldwide.”

The acquisition of CoAxia’s intellectual property also offers synergy with Zoll’s acute critical care portfolio of products such as temperature management, which may reduce reperfusion injury following ischemia by using balloon catheters. The devices could also offer significant potential applications in blood flow redistribution for trauma, cardiac arrest, coronary procedures, surgical blood loss, and renal perfusion.

Related Links:

ZOLL
CoAxia



ECR
Cincinnati Sub-Zero
Anetic Aid

Channels

Women's Health

view channel

Maternal Iron Intake Linked to Autism Risk

A new study reveals that mothers of children with autism spectrum disorder (ASD) are less likely to have taken iron supplements before and during their pregnancies. Researchers at the University of California Davis (UCD; USA) and the UCD Mind Institute Clinic (Sacramento, CA, USA) analyzed data from 866 mother-child... Read more

Health IT

view channel

Doctors Claim EHRs Do Not Save Money or Time

A recent survey claims that 75% of physicians in the United States who use electronic health records (EHRs) say they are not cost- or time-effective, but do have value in terms of providing data. The Deloitte (New York, NY, USA) 2014 Survey examined US physicians’ current use and overall views of mobile health (mHealth)... Read more

Hospital News

view channel
Image: Artist rendering of the new Memorial Hermann Cypress medical campus (Photo courtesy Memorial Hermann Health System).

Memorial Hermann to Construct State-of-the-Art Hospital

Memorial Hermann Health System (Houston, TX, USA) is planning to construct a new medical campus in Cypress (TX, USA), with an investment of approximately USD 168 million. The new campus is being built... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.